P
ProHub
English 简体中文 繁體中文
Medium Financial Analysis Merger & Acquisition

Goodbye Horses

#Healthcare
ProHub Comment

This is a sophisticated capital allocation case that combines strategic divestiture with portfolio optimization. The case requires candidates to identify which business unit to divest (Animal Health—lowest growth, misaligned with core mission), calculate the capital proceeds ($14.7B), and then apply a profitability index framework to maximize NPV across competing projects given capital constraints. Strong performance requires both quantitative rigor and qualitative risk assessment.

Estimated Time 26 minutes
Difficulty Medium
Source Duke
10 / 100
Your client is the CFO of Aperture Laboratories, a leading US biopharmaceutical company with a market cap >$150B. Aperture develops and manufactures a diversified range of products and in particular prides itself on saving millions of human lives every year. The company is under investor pressure because of its slow firm value growth over the next 10 years. Investors are very anxious to see significant changes announced at the firm in the next quarter. The CFO has already identified and evaluated a number of high-growth, promising, but capital-intensive projects, and she does not have enough cash to invest in any of the opportunities—what dose she need to do next?

Clarifying Information

  1. Unknown to the CFO until now, the business development team has retained JP Morgan to assess the sale-ability of the Animal Health business. They have identified that Aperture will likely receive a 3.5x enterprise value to sales multiple for the animal health business.
  2. If asked about taxes, tell the interviewee the deal has been structured by JP Morgan to be tax-free.
  3. If asked, tell the interviewee that the NPV includes the capital investment.
Mock Interview
Interviewer

Your client is the CFO of Aperture Laboratories, a leading US biopharmaceutical company with a market cap >$150B. Aperture develops and manufactures a diversified range of products and in particular prides itself on saving millions of human lives every year. The company is under investor pressure because of its slow firm value growth over the next 10 years. Investors are very anxious to see significant changes announced at the firm in the next quarter. The CFO has already identified and evaluated a number of high-growth, promising, but capital-intensive projects, and she does not have enough cash to invest in any of the opportunities—what dose she need to do next?

You

Thanks. Before analyzing, I'd like to clarify a few key questions...

Interviewer

Good question. Let me provide some background information...

You

Based on this, I suggest analyzing from these dimensions...

AI Score
Structure Analysis Communication Business Sense Quantitative
Practicing...
Score coming soon
Practice this case with AI Mock Interview

Aperture Laboratories faces investor pressure for growth but lacks capital to fund promising high-return projects. The solution involves divesting the low-growth Animal Health division for $14.7B, then strategically investing in three projects (GLP-1 agonist acquisition, product formulation research, and manufacturing cost-cutting) that together generate $22B in NPV while consuming $14B of proceeds, with risk mitigation strategies for execution challenges.

Key Insights:

  1. Strategic fit and mission alignment are as important as financial metrics in divestiture decisions (Animal Health misaligned with ‘saving human lives’ mission)
  2. Profitability index (NPV/Capital) is the optimal tool for capital allocation under constraints, revealing that projects 2, 3, and 5 maximize returns
  3. Integration of quantitative analysis (financial calculations) with qualitative considerations (project timeline, buyer availability, execution risk) distinguishes excellent candidates
  4. Final recommendation should address not just the main strategy but also deployment of residual capital ($700M) and mitigation strategies for key execution risks